This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Cyclacel Pharmaceuticals (cancer therapeutics) grossed $45.3mm through the private placement of 6.4mm units priced at $7.05 apiece (a slight discount to the market average). Each unit consisted of one common share and a warrant to purchase 0.40 shares of common stock. Investors, which included Atlas Master Fund, Visium, SF Capital, Capital Ventures, Magnetar, Federated Kaufman, Deerfield Partners, Baker Biotech, and Red Abbey, also received five-year warrants to purchase an additional 2.57mm common shares at $7 each. The company will use the funds for development of its anticancer candidates seliciclib, sapacitabine, and CYC116.
Private Investment in Public Equity
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?